Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia

Nuche-Berenguer, Bernardo, Lozano, Daniel, Gutiérrez-Rojas, Irene, Moreno, Paola, Mariñoso, María L, Esbrit, Pedro, Villanueva-Peñacarrillo, María L · 2011 · Journal of Endocrinology

Abstract

Increased fat mass contributes to bone deterioration. Glucagon-like peptide 1 (GLP-1) and its related peptide exendin 1–39 amide (Ex-4), two lipid-lowering peptides, exert osteogenic effects in diabetic states. We examined the actions of 3-day administration of GLP-1 or Ex-4 on bone remodeling markers and on bone mass and structure in hyperlipidic (HL) and hypercaloric rats. Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days. After killing, tibiae were removed for total RNA and protein isolation, as well as femurs and L1–L4 vertebrae for bone mass and quality assessment. Body weight and plasma insulin were unaltered in HL rats, which showed osteopenia (by dual-energy X-ray absorptiometry), associated with hyperglycemia, hypertriglyceridemia, and hypercholesterolemia. GLP-1 or Ex-4 administration decreased the levels of glucose, triglycerides, and total cholesterol in plasma but increased osteocalcin (OC) gene expression and the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) ratio – at the expense of an augmented OPG – above corresponding control values in the tibia. Each tested peptide similarly reversed the decreased femoral and vertebral bone mass in these rats, whereas the deteriorated trabecular structure in the vertebrae improved associated with normalization of bone remodeling. These findings demonstrate that GLP-1 and Ex-4 are similarly efficient in reversing the bone alterations in this HL rat model, which has proven to be useful for studying the fat–bone relationships.

Overview

Integrity signals

Registry

Crossref · 10.1530/joe-11-0015

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

See all 96

Metadata

Authors
Nuche-Berenguer, B., Lozano, D., Gutiérrez-Rojas, I., Moreno, P., Mariñoso, M. L., Esbrit, P., & Villanueva-Peñacarrillo, M. L.
Affiliations
Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ES)
Venue
Journal of Endocrinology
Published
2011-03-03
Volume
209
Issue
2
Pages
203-210
ISSN
  • 0022-0795 (ISSN-L)
  • 1479-6805
OpenAlex
W2129404964
Cited by
96
References
51
Citations by year
2026: 3 · 2025: 7 · 2024: 7 · 2023: 6 · 2022: 6 · 2021: 3 · 2020: 5 · 2019: 8 · 2018: 3 · 2017: 8 · 2016: 7 · 2015: 11 · 2014: 5 · 2013: 10 · 2012: 5
FWCI
2.85
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas
  • Instituto de Salud Carlos III (RD06/0013)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
glucagon-like peptide-1, exendin-4, hyperlipidemia, osteopenia, bone remodeling, osteocalcin, osteoprotegerin, RANKL, hypercaloric diet, bone mass, trabecular bone microarchitecture, hypertriglyceridemia, hypercholesterolemia, hyperglycemia
MeSH terms
Exenatide, Animals, Bone Diseases, Metabolic, Dietary Fats, Drug Evaluation, Preclinical, Humans, Hyperlipidemias, Hypoglycemic Agents, Lumbar Vertebrae, Osteogenesis, Peptides, Venoms, Biomarkers, Bone Density, Rats, Wistar, Rats, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. https://app.cochat.ai/papers/10.1530/joe-11-0015
The paper
Nuche-Berenguer, B., Lozano, D., Gutiérrez-Rojas, I., Moreno, P., Mariñoso, M. L., Esbrit, P., & Villanueva-Peñacarrillo, M. L. (2011). GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. Journal of Endocrinology. https://doi.org/10.1530/joe-11-0015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.